Axogen Inc (AXGN) - Total Assets
Based on the latest financial reports, Axogen Inc (AXGN) holds total assets worth $216.40 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Axogen Inc book value and equity for net asset value and shareholders' equity analysis.
Axogen Inc - Total Assets Trend (1986–2024)
This chart illustrates how Axogen Inc's total assets have evolved over time, based on quarterly financial data.
Axogen Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Axogen Inc's total assets of $216.40 Million consist of 48.7% current assets and 51.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.5% |
| Accounts Receivable | $24.11 Million | 11.8% |
| Inventory | $33.18 Million | 16.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.58 Million | 2.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2024)
This chart illustrates how Axogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AXGN market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Axogen Inc's current assets represent 48.7% of total assets in 2024, an increase from 35.8% in 1986.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2024, down from 14.9% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 1986.
- Asset Diversification: The largest asset category is inventory at 16.3% of total assets.
Axogen Inc Competitors by Total Assets
Key competitors of Axogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Axogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.09 | 3.74 | 6.36 |
| Quick Ratio | 2.64 | 2.47 | 5.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $86.45 Million | $63.22 Million | $122.42 Million |
Axogen Inc - Advanced Valuation Insights
This section examines the relationship between Axogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.49 |
| Latest Market Cap to Assets Ratio | 8.60 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | $203.73 Million |
| Market Capitalization | $1.75 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Axogen Inc's assets at a significant premium (8.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Axogen Inc's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Axogen Inc (1986–2024)
The table below shows the annual total assets of Axogen Inc from 1986 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $203.73 Million | +3.51% |
| 2023-12-31 | $196.83 Million | +0.74% |
| 2022-12-31 | $195.39 Million | -6.07% |
| 2021-12-31 | $208.02 Million | +3.30% |
| 2020-12-31 | $201.38 Million | +30.22% |
| 2019-12-31 | $154.64 Million | -3.45% |
| 2018-12-31 | $160.17 Million | +172.06% |
| 2017-12-31 | $58.87 Million | +26.99% |
| 2016-12-31 | $46.36 Million | +23.48% |
| 2015-12-31 | $37.55 Million | +128.93% |
| 2014-12-31 | $16.40 Million | -40.76% |
| 2013-12-31 | $27.68 Million | +36.84% |
| 2012-12-31 | $20.23 Million | +61.91% |
| 2011-12-31 | $12.50 Million | +23.18% |
| 2010-12-31 | $10.14 Million | -39.65% |
| 2009-12-31 | $16.81 Million | +3106.23% |
| 2008-12-31 | $524.24K | -52.34% |
| 2007-12-31 | $1.10 Million | -27.38% |
| 2006-12-31 | $1.51 Million | -17.00% |
| 2005-12-31 | $1.82 Million | -34.90% |
| 2004-12-31 | $2.80 Million | +4.18% |
| 2003-12-31 | $2.69 Million | -35.17% |
| 2002-12-31 | $4.15 Million | -34.64% |
| 2001-12-31 | $6.35 Million | -25.07% |
| 2000-12-31 | $8.47 Million | -3.70% |
| 1999-12-31 | $8.80 Million | -16.98% |
| 1998-12-31 | $10.60 Million | -10.17% |
| 1997-12-31 | $11.80 Million | -4.07% |
| 1996-12-31 | $12.30 Million | -3.15% |
| 1995-12-31 | $12.70 Million | 0.00% |
| 1994-12-31 | $12.70 Million | 0.00% |
| 1993-12-31 | $12.70 Million | +15.45% |
| 1992-12-31 | $11.00 Million | +5.77% |
| 1991-12-31 | $10.40 Million | +9.47% |
| 1990-12-31 | $9.50 Million | +13.10% |
| 1989-12-31 | $8.40 Million | -85.57% |
| 1988-12-31 | $58.20 Million | +743.48% |
| 1987-12-31 | $6.90 Million | +2.99% |
| 1986-12-31 | $6.70 Million | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porc… Read more